ATE140731T1 - Plasmidvektor mit pectatlyase-signalsequenz - Google Patents
Plasmidvektor mit pectatlyase-signalsequenzInfo
- Publication number
- ATE140731T1 ATE140731T1 AT89901763T AT89901763T ATE140731T1 AT E140731 T1 ATE140731 T1 AT E140731T1 AT 89901763 T AT89901763 T AT 89901763T AT 89901763 T AT89901763 T AT 89901763T AT E140731 T1 ATE140731 T1 AT E140731T1
- Authority
- AT
- Austria
- Prior art keywords
- pectatlyase
- signal sequence
- plasmid vector
- vector
- thaumatin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
- C07K14/43—Sweetening agents, e.g. thaumatin, monellin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Botany (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14203988A | 1988-01-11 | 1988-01-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE140731T1 true ATE140731T1 (de) | 1996-08-15 |
Family
ID=22498331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT89901763T ATE140731T1 (de) | 1988-01-11 | 1989-01-09 | Plasmidvektor mit pectatlyase-signalsequenz |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0396612B1 (de) |
| JP (1) | JP2980626B2 (de) |
| AT (1) | ATE140731T1 (de) |
| CA (1) | CA1338807C (de) |
| DE (1) | DE68926882T2 (de) |
| WO (1) | WO1989006283A1 (de) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5576195A (en) * | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| CA1341235C (en) * | 1987-07-24 | 2001-05-22 | Randy R. Robinson | Modular assembly of antibody genes, antibodies prepared thereby and use |
| ES2080689B1 (es) * | 1994-04-21 | 1996-09-01 | Urquima Sa | Procedimiento de obtencion de un edulcorante natural proteico. |
| GB9610967D0 (en) | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
| EP1048732A1 (de) * | 1999-04-26 | 2000-11-02 | F. Hoffmann-La Roche Ag | Verfahren zur Herstellung von natürlich gefalteten und sekretierten Proteinen |
| EP1077263A1 (de) * | 1999-07-29 | 2001-02-21 | F.Hoffmann-La Roche Ag | Verfahren zur Herstellung von natürlich gefalteten und sekretierten Proteinen durch Co-Sekretion von Chaperonen |
| JP2003524018A (ja) | 2000-02-24 | 2003-08-12 | アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ | フィブロネクチンのｅｄ‐ｂドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用 |
| UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
| US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
| US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
| US9708410B2 (en) | 2003-05-30 | 2017-07-18 | Janssen Biotech, Inc. | Anti-tissue factor antibodies and compositions |
| CA2589937C (en) * | 2004-12-07 | 2014-04-22 | Lonza Ag | Rhamnose promoter expression system |
| DE102006044841A1 (de) | 2006-09-22 | 2008-04-03 | Wacker Chemie Ag | Signalpeptid zur Produktion von rekombinanten Proteinen |
| EP2650014A2 (de) | 2008-06-20 | 2013-10-16 | Wyeth LLC | Zusammensetzungen und Verfahren zur Verwendung von ORF1358 von Beta-hämolytischen Streptokokken-stämmen |
| KR20160116056A (ko) | 2008-08-14 | 2016-10-06 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 항-ｉｌ-12/ｉｌ-23 항체 |
| CN102459591B (zh) | 2009-05-20 | 2015-05-13 | 诺维莫尼公司 | 合成性的多肽文库以及用于建立具有天然多样性的多肽变体的方法 |
| WO2015097536A2 (en) | 2013-12-24 | 2015-07-02 | Janssen Pharmaceutical Nv | Anti-vista antibodies and fragments |
| CA2990360C (en) | 2015-06-24 | 2024-02-13 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
| WO2017137830A1 (en) | 2016-02-12 | 2017-08-17 | Janssen Pharmaceutica Nv | Anti-vista (b7h5) antibodies |
| CN109071653A (zh) | 2016-03-29 | 2018-12-21 | 詹森生物科技公司 | 用增加的抗-il12和/或-23抗体给药间隔治疗牛皮癣 |
| WO2017175058A1 (en) | 2016-04-07 | 2017-10-12 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
| CA3037961A1 (en) | 2016-09-30 | 2018-04-05 | Janssen Biotech, Inc. | Safe and effective method of treating psoriasis with anti-il23 specific antibody |
| US11208474B2 (en) | 2016-11-16 | 2021-12-28 | Janssen Biotech, Inc. | Method of treating psoriasis with anti-IL23 specific antibody |
| WO2018140121A1 (en) | 2017-01-30 | 2018-08-02 | Janssen Biotech, Inc. | Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis |
| MX2019009377A (es) | 2017-02-07 | 2019-12-11 | Janssen Biotech Inc | Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa. |
| TW201922780A (zh) | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法 |
| JP2021502349A (ja) | 2017-11-06 | 2021-01-28 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｉｌ２３特異的抗体で乾癬性関節炎を治療する安全かつ有効な方法 |
| WO2019150309A1 (en) | 2018-02-02 | 2019-08-08 | Hammack Scott | Modulators of gpr68 and uses thereof for treating and preventing diseases |
| MX2020009265A (es) | 2018-03-05 | 2020-10-01 | Janssen Biotech Inc | Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23. |
| US20200025776A1 (en) | 2018-07-18 | 2020-01-23 | Janssen Biotech, Inc. | Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody |
| IL326284A (en) | 2018-09-24 | 2026-04-01 | Janssen Biotech Inc | A safe and effective method for treating ulcerative colitis with an anti-IL12/IL23 antibody |
| IL283192B2 (en) | 2018-11-20 | 2025-10-01 | Janssen Biotech Inc | A safe and effective method for treating psoriasis with a specific anti-IL-23 antibody |
| MA54562A (fr) | 2018-12-18 | 2021-10-27 | Janssen Biotech Inc | Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23 |
| JP7689074B2 (ja) | 2019-01-15 | 2025-06-05 | ヤンセン バイオテツク，インコーポレーテツド | 若年性特発性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法 |
| WO2020152544A1 (en) | 2019-01-23 | 2020-07-30 | Janssen Biotech, Inc. | Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis |
| KR20210141998A (ko) | 2019-03-14 | 2021-11-23 | 얀센 바이오테크 인코포레이티드 | 항-tnf 항체 조성물의 제조 방법 |
| EP3938384A4 (de) | 2019-03-14 | 2022-12-28 | Janssen Biotech, Inc. | Herstellungsverfahren zur herstellung von anti-il12/il23-antikörperzusammensetzungen |
| WO2020183269A1 (en) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
| EA202192505A1 (ru) | 2019-03-14 | 2022-03-29 | Янссен Байотек, Инк. | Способы получения композиций антитела к фно |
| JP2022526493A (ja) | 2019-03-18 | 2022-05-25 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｉｌ１２／ｉｌ２３抗体を用いた小児被験者の乾癬の治療方法 |
| JP7805788B2 (ja) | 2019-05-23 | 2026-01-26 | ヤンセン バイオテツク，インコーポレーテツド | Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法 |
| JP2022536279A (ja) | 2019-06-03 | 2022-08-15 | ヤンセン バイオテツク，インコーポレーテツド | 乾癬性関節炎を治療するための抗ｔｎｆ抗体組成物及び方法 |
| MX2021014882A (es) | 2019-06-03 | 2022-03-25 | Janssen Biotech Inc | Anticuerpos anti-tnf, composiciones y métodos para el tratamiento de la espondilitis anquilosante activa. |
| MA56124A (fr) | 2019-06-04 | 2022-04-13 | Janssen Biotech Inc | Méthode sûre et efficace de traitement de l'arthrite psoriasique au moyen d'un anticorps spécifique anti-il23 |
| WO2021028752A1 (en) | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Anti-tfn antibodies for treating type i diabetes |
| US20210347880A1 (en) | 2020-05-05 | 2021-11-11 | Janssen Biotech, Inc. | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody |
| IL298389A (en) | 2020-05-21 | 2023-01-01 | Janssen Biotech Inc | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
| WO2022013745A1 (en) | 2020-07-13 | 2022-01-20 | Janssen Biotech, Inc. | Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody |
| US20220073603A1 (en) | 2020-07-30 | 2022-03-10 | Janssen Biotech, Inc. | Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody |
| IL305802A (en) | 2021-03-12 | 2023-11-01 | Janssen Biotech Inc | A safe and effective method for the treatment of rheumatoid arthritis with a specific anti-IL23 antibody |
| EP4305062A1 (de) | 2021-03-12 | 2024-01-17 | Janssen Biotech, Inc. | Verfahren zur behandlung von patienten mit psoriasisarthritis mit unzureichender reaktion auf eine tnf-therapie mit anti-il23-spezifischem antikörper |
| JP2024527581A (ja) | 2021-07-09 | 2024-07-25 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｉｌ１２／ｉｌ２３抗体組成物を生産するための製造方法 |
| EP4367136A1 (de) | 2021-07-09 | 2024-05-15 | Janssen Biotech, Inc. | Herstellungsverfahren zur herstellung von anti-tnf-antikörperzusammensetzungen |
| US12534524B2 (en) | 2021-07-09 | 2026-01-27 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-TNF antibody compositions |
| EP4423126B1 (de) | 2021-10-29 | 2026-05-06 | Janssen Biotech, Inc. | Verfahren zur behandlung von morbus crohn mit anti-il23-spezifischem antikörper |
| EP4433501A1 (de) | 2021-11-15 | 2024-09-25 | Janssen Biotech, Inc. | Verfahren zur behandlung von morbus crohn mit anti-il23-spezifischem antikörper |
| US20230159633A1 (en) | 2021-11-23 | 2023-05-25 | Janssen Biotech, Inc. | Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody |
| JP2025512860A (ja) | 2022-03-30 | 2025-04-22 | ヤンセン バイオテツク，インコーポレーテツド | Ｉｌ－２３に特異的な抗体によって軽度から中等度の乾癬を治療する方法 |
| EP4526342A1 (de) | 2022-05-18 | 2025-03-26 | Janssen Biotech, Inc. | Verfahren zur bewertung und behandlung von psoriasisarthritis mit il23-antikörper |
| AU2023383916A1 (en) | 2022-11-22 | 2025-07-10 | Janssen Biotech, Inc. | Method of treating ulcerative colitis with anti-il23 specific antibody |
| CA3249015A1 (en) | 2024-03-20 | 2025-10-31 | Janssen Biotech, Inc. | Methods of treating crohn’s disease with anti-il23 specific antibody |
| WO2025262604A1 (en) | 2024-06-17 | 2025-12-26 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
| CA3258952A1 (en) | 2024-06-27 | 2026-03-01 | Janssen Biotech, Inc. | Methods of treating ulcerative colitis with anti-il23 specific antibody |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6030687A (ja) * | 1983-08-01 | 1985-02-16 | Wakunaga Seiyaku Kk | Ｄνａ遺伝子，その製造法およびそれを含むプラスミド |
| GB8702475D0 (en) * | 1987-02-04 | 1987-03-11 | Ciba Geigy Ag | Expression system |
| CA1341235C (en) * | 1987-07-24 | 2001-05-22 | Randy R. Robinson | Modular assembly of antibody genes, antibodies prepared thereby and use |
-
1989
- 1989-01-09 EP EP89901763A patent/EP0396612B1/de not_active Expired - Lifetime
- 1989-01-09 JP JP1501661A patent/JP2980626B2/ja not_active Expired - Lifetime
- 1989-01-09 WO PCT/US1989/000077 patent/WO1989006283A1/en not_active Ceased
- 1989-01-09 AT AT89901763T patent/ATE140731T1/de not_active IP Right Cessation
- 1989-01-09 DE DE68926882T patent/DE68926882T2/de not_active Expired - Lifetime
- 1989-01-10 CA CA000587885A patent/CA1338807C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO1989006283A1 (en) | 1989-07-13 |
| EP0396612A1 (de) | 1990-11-14 |
| DE68926882T2 (de) | 1997-02-13 |
| JP2980626B2 (ja) | 1999-11-22 |
| DE68926882D1 (de) | 1996-08-29 |
| JPH04503151A (ja) | 1992-06-11 |
| EP0396612A4 (en) | 1991-10-02 |
| EP0396612B1 (de) | 1996-07-24 |
| CA1338807C (en) | 1996-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE68926882D1 (de) | Plasmidvektor mit pectatlyase-signalsequenz | |
| PT88115A (pt) | Dna constructs containing a kluyveromyces alpha-factor leader sequence for directing secretion of heterologous polypetides | |
| PT100637A (pt) | Receptor ctla4 e metodos para a sua utilizacao | |
| DK666888D0 (da) | Human vaevsfaktor-relaterende dna-segmenter, polypeptider og antistoffer | |
| AU573523B2 (en) | Functional human urokinase proteins | |
| ATE46536T1 (de) | Verfahren zur herstellung von reifen proteinen in wirtzellen von wirbeltieren. | |
| ES2072892T3 (es) | Proteina receptora para un factor 2 estimulante de celulas b humanas. | |
| DE69128285D1 (de) | Expression rekombinanter polypeptide mit verbesserter möglichkeit zur reinigung | |
| AU1986588A (en) | Growth hormone receptor | |
| NZ222856A (en) | Equine interferon gamma (eq ifn alpha), dna sequences for its recombinant production and monoclonal antibodies thereto | |
| DE60137829D1 (de) | Menschliche stra6 polypeptide | |
| ES8505406A1 (es) | Procedimiento de obtener y aislar hibridomas secretores de anticuerpos, procedimiento de obtener anticuerpos y metodo de obtener polipeptidos | |
| DK1520860T3 (da) | Rekombinant protein PilC, fremgangsmåde til dets fremstilling og anvendelse deraf | |
| GB2171703B (en) | Expression-secretion vector for gene expression and protein secretion, recombinant dna including the vector, and method of producing proteins by use of the re | |
| ES2113342T3 (es) | Expresion de la sub-unidad ligante de la toxina colerica con la ayuda de promotores extraños y/o secuencias lideres. | |
| ES8405842A1 (es) | Procedimiento de producir razas estables de celulas de mamiferos | |
| DK453285A (da) | Syntetisk signalsekvens og dens anvendelse, bl.a. til transportekspressioner af proteiner | |
| DE3688974D1 (de) | Expressionssysteme zur überproduktion gewünschter proteine. | |
| FI934079L (fi) | Menetelmä fuusioproteiinin valmistamiseksi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| EELA | Cancelled due to lapse of time |